Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium diatrizoate + sodium picosulfate is a combination regimen used for bowel preparation and fecal tagging in computed tomographic colonography (CTC). Sodium diatrizoate is an iodinated, radiopaque contrast medium that serves as a fecal tagging agent; it increases the radiodensity of residual stool, allowing for better differentiation from colonic polyps during imaging. Sodium picosulfate is a stimulant laxative that is hydrolyzed by colonic bacteria into its active metabolite, bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates peristalsis and increases water and electrolyte secretion in the large intestine. This combination is often employed in "minimum-laxative" protocols to improve patient compliance and tolerance compared to high-volume polyethylene glycol (PEG) preparations, while maintaining diagnostic sensitivity for detecting colorectal polyps.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium diatrizoate + sodium picosulfate.